CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 30 enrolled
Drug / intervention
Rifaximin intervention +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02280044
NCT02280044Phase 3Completed
CompareCT.gov

Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni

Johns Hopkins Bloomberg School of Public Health·interventional·Posted Oct 31, 2014·Updated Nov 20, 2018

In Brief

A Phase 3 clinical trial evaluating Rifaximin intervention and Placebo intervention for Dysentery and 2 related conditions. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This study is a randomized, double-blinded, placebo-controlled, in-patient trial evaluating the prophylactic efficacy of rifaximin against campylobacteriosis following challenge with C. jejuni.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDysentery, Diarrhea, Enteric Campylobacteriosis
CountriesUnited States
CollaboratorsNaval Medical Research Center, Uniformed Services University of the Health Sciences

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 31, 2014
Enrollment StartOct 1, 2014
Primary CompletionAug 9, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.7 years ago

Interventions

Rifaximin interventionbiological

Rifaximin administered then Challenge with C jejuni

Placebo interventionbiological

Placebo administered then Challenge with C jejuni